Do Young Kim

Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial

Riccardo Lencioni, Josep M. Llovet, Guohong Han et al. · Journal of Hepatology · 2016 · 680 citations · Full text

Doxorubicin-eluting Beads, Intermediate Stage Hcc, Pharmacology +8

Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score

Hwai‐I Yang, Man‐Fung Yuen, Henry Lik‐Yuen Chan et al. · The Lancet Oncology · 2011 · 649 citations · Full text

Hepatitis D, Epidemiology, Hepatology +12

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 415 citations · Full text

Surgical Oncology, Hepatology, Medicine +8

Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008‐2011)

Yong‐ho Lee, Seung Up Kim, Kijun Song et al. · Hepatology · 2015 · 337 citations · Full text

A Liver Stiffness Measurement-Based, Noninvasive Prediction Model for High-Risk Esophageal Varices in B-Viral Liver Cirrhosis

Beom Kyung Kim, Kwang‐Hyub Han, Jun Yong Park et al. · The American Journal of Gastroenterology · 2010 · 228 citations · Full text